Immune checkpoints have been playing a significant role in cancer immunotherapy. They are a serious of co-stimulatory and inhibitory signals for regulating the antigen recognition. The cancer cells cleverly escape from immunity by dysregulating immune checkpoint signaling. So agonists of co-stimulatory signals or antagonists of inhibitory signals function as good ways for cancer therapy. Over these years, remarkable successes have been achieved in immune checkpoint therapy : CTLA-4 and PD1- PD-L1 inhibitors have already been approved for cancer therapy with effective efficacy. Multiple additional researches on other immune checkpoints have also stepped into clinical trials, predicting new hope for conquering cancer.
|? Validated bioactivity & High purity (SDS-PAGE);||? His-tagged, Fc-tagged and tag free proteins|
|? Mutiple species: Human, Mouse, Canine, Rat, Rhesus,Cynomolgus;||? Endotoxin less than 1EU/μg by the LAL method.|
|? Produced in house & Animal free|
|Fig .1 The purity of PD-L1 protein (10084-H02H) was >95% as determined by SDS-PAGE.||Fig .2 The activity assay (ED50=59.8 ng/mL) of CD27 protein (10039-H03H）by binding to CD70 Protein.|
Sino Biological Inc. has researched and developed proteins for almost 50 immune checkpoints as shown below. Recombinant immune checkpoint proteins cover multiple species and various tags. Binding activity has also been assayed and confirmed. All the proteins can be customized. If you cannot find a desired one, please contact [email protected]